Jasper Therapeutics
Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. They aim to treat conditions like chronic urticaria, asthma, and other mast cell-driven diseases by depleting mast cells through targeted therapy. The company is led by an experienced management team and scientific advisory board, and is actively conducting clinical trials to evaluate the safety and efficacy of briquilimab.
Industries
Nr. of Employees
small (1-50)
Jasper Therapeutics
Redwood City, California, United States, North America
Products
Briquilimab
A humanized, aglycosylated anti‑KIT (CD117) monoclonal antibody designed to block stem cell factor–KIT interaction, induce mast cell apoptosis and act as a targeted conditioning agent for hematopoietic stem cell engraftment.
mRNA stem cell graft platform
Platform for transient mRNA reprogramming of donor or gene‑edited hematopoietic stem cells to confer temporary proliferative/survival advantages that enhance engraftment without permanent genomic modification.
Humanized c‑Kit mouse model (proprietary)
A proprietary mouse model engineered to allow direct testing of antibodies targeting the human KIT receptor to improve preclinical translatability.
Briquilimab
A humanized, aglycosylated anti‑KIT (CD117) monoclonal antibody designed to block stem cell factor–KIT interaction, induce mast cell apoptosis and act as a targeted conditioning agent for hematopoietic stem cell engraftment.
mRNA stem cell graft platform
Platform for transient mRNA reprogramming of donor or gene‑edited hematopoietic stem cells to confer temporary proliferative/survival advantages that enhance engraftment without permanent genomic modification.
Humanized c‑Kit mouse model (proprietary)
A proprietary mouse model engineered to allow direct testing of antibodies targeting the human KIT receptor to improve preclinical translatability.
Services
Company‑sponsored clinical trials
Design and conduct of early‑phase clinical trials (Phase 1/1b/2a) evaluating KIT‑targeting antibodies in mast cell diseases and evaluating antibody conditioning in stem cell transplant indications.
Investigator‑sponsored trial support and investigational product supply
Supply of investigational antibody therapies and protocol support for investigator‑led studies (e.g., stem cell transplant conditioning studies at academic centers).
Research collaborations and partnership development
Collaborative research partnerships with academic institutions and external sponsors to advance preclinical models, translational studies and clinical evaluations.
Company‑sponsored clinical trials
Design and conduct of early‑phase clinical trials (Phase 1/1b/2a) evaluating KIT‑targeting antibodies in mast cell diseases and evaluating antibody conditioning in stem cell transplant indications.
Investigator‑sponsored trial support and investigational product supply
Supply of investigational antibody therapies and protocol support for investigator‑led studies (e.g., stem cell transplant conditioning studies at academic centers).
Research collaborations and partnership development
Collaborative research partnerships with academic institutions and external sponsors to advance preclinical models, translational studies and clinical evaluations.
Expertise Areas
- Antibody therapeutics development
- Mast cell biology and immunology
- Clinical trial management (early‑phase)
- Hematopoietic stem cell transplant conditioning
Key Technologies
- Monoclonal antibody therapeutics targeting KIT/CD117
- Antibody engineering (humanized, aglycosylated formats)
- mRNA‑based transient stem cell modification
- Humanized c‑Kit mouse models